Key Points
- Addus HomeCare director Esteban Lopez sold 250 shares on May 21 at $93.00 each, totaling $23,250. After the sale, he still owned 3,200 shares, and the transaction cut his position by about 7.25%.
- The company recently beat earnings expectations by reporting $1.62 EPS versus the $1.52 consensus, while revenue came in at $363.5 million, slightly below estimates but still up 7.7% year over year.
- Analysts remain mixed but generally positive on ADUS, with a consensus rating of “Moderate Buy” and an average price target of $131.22, though Barclays recently lowered its target and maintained an underweight rating.
Addus HomeCare Corporation (NASDAQ:ADUS - Get Free Report) Director Esteban Lopez sold 250 shares of the firm's stock in a transaction dated Thursday, May 21st. The shares were sold at an average price of $93.00, for a total transaction of $23,250.00. Following the sale, the director directly owned 3,200 shares in the company, valued at approximately $297,600. The trade was a 7.25% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.
Esteban Lopez also recently made the following trade(s):
- On Tuesday, May 19th, Esteban Lopez sold 250 shares of Addus HomeCare stock. The shares were sold at an average price of $93.00, for a total transaction of $23,250.00.
Addus HomeCare Stock Performance
Shares of NASDAQ ADUS opened at $92.65 on Friday. The firm's 50-day moving average price is $95.72 and its 200-day moving average price is $105.47. The company has a quick ratio of 1.83, a current ratio of 1.83 and a debt-to-equity ratio of 0.08. The company has a market cap of $1.73 billion, a PE ratio of 17.13, a PEG ratio of 1.28 and a beta of 0.92. Addus HomeCare Corporation has a 52-week low of $89.76 and a 52-week high of $124.43.
Addus HomeCare (NASDAQ:ADUS - Get Free Report) last announced its quarterly earnings results on Monday, May 4th. The company reported $1.62 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.52 by $0.10. The firm had revenue of $363.50 million for the quarter, compared to the consensus estimate of $366.41 million. Addus HomeCare had a net margin of 6.89% and a return on equity of 9.80%. The business's quarterly revenue was up 7.7% compared to the same quarter last year. During the same quarter last year, the firm posted $1.42 EPS. As a group, analysts anticipate that Addus HomeCare Corporation will post 6.24 EPS for the current year.
Institutional Trading of Addus HomeCare
Institutional investors and hedge funds have recently modified their holdings of the company. Global Retirement Partners LLC raised its position in shares of Addus HomeCare by 395.7% during the 4th quarter. Global Retirement Partners LLC now owns 233 shares of the company's stock valued at $25,000 after purchasing an additional 186 shares during the period. Larson Financial Group LLC lifted its holdings in shares of Addus HomeCare by 133.3% in the third quarter. Larson Financial Group LLC now owns 238 shares of the company's stock worth $28,000 after buying an additional 136 shares in the last quarter. Acumen Wealth Advisors LLC purchased a new position in shares of Addus HomeCare in the fourth quarter worth $29,000. Arax Advisory Partners lifted its holdings in shares of Addus HomeCare by 95.8% in the fourth quarter. Arax Advisory Partners now owns 280 shares of the company's stock worth $30,000 after buying an additional 137 shares in the last quarter. Finally, Private Trust Co. NA lifted its holdings in shares of Addus HomeCare by 65.5% in the fourth quarter. Private Trust Co. NA now owns 283 shares of the company's stock worth $30,000 after buying an additional 112 shares in the last quarter. 95.35% of the stock is currently owned by institutional investors.
Wall Street Analyst Weigh In
A number of analysts have recently issued reports on ADUS shares. Royal Bank Of Canada reaffirmed an "outperform" rating and set a $139.00 price target on shares of Addus HomeCare in a report on Wednesday, February 25th. Barclays dropped their price objective on shares of Addus HomeCare from $102.00 to $92.00 and set an "underweight" rating on the stock in a report on Friday, May 15th. Citizens Jmp reissued a "market outperform" rating and issued a $142.00 price objective on shares of Addus HomeCare in a report on Monday, May 18th. Stephens dropped their price objective on shares of Addus HomeCare from $140.00 to $135.00 and set an "overweight" rating on the stock in a report on Wednesday, February 25th. Finally, KeyCorp reissued an "overweight" rating on shares of Addus HomeCare in a report on Wednesday, February 25th. One research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Addus HomeCare presently has an average rating of "Moderate Buy" and a consensus target price of $131.22.
Read Our Latest Report on ADUS
Addus HomeCare Company Profile
(
Get Free Report)
Addus HomeCare (NASDAQ: ADUS) is a leading provider of home and community-based care services for elderly, disabled, and medically complex individuals across the United States. Through a network of company-owned and franchise locations, the company delivers a broad spectrum of non-medical personal care and licensed home health services designed to support clients' independence and quality of life.
The company's core offerings include personal care assistance—covering daily living activities, medication reminders, and light housekeeping—and skilled home health services delivered under the supervision of registered nurses and licensed therapists.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
